Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of CC-1 in Men With Biochemical Recurrence of Prostate Cancer
NCT05646550Phase 1Recruiting
- Sponsor
- University Hospital Tübingen
- Start
- Nov 2022
- Primary completion
- Dec 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of CC-1 in prostate cancer (PCa) (2 arms), sponsored by University Hospital Tübingen. Primary endpoints: Maximum Tolerated Dose and Recommended Phase II Dose. Started Nov 2022; status: recruiting.
02
Drugs
CC-1
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05646550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05646550.